<DOC>
	<DOCNO>NCT02618187</DOCNO>
	<brief_summary>A Multiple Dose Study Evaluate Safety , Tolerability Microbiome Dynamics SER-287 Subjects Mild-to-Moderate Ulcerative Colitis .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Microbiome Dynamics SER-287 Subjects With Ulcerative Colitis</brief_title>
	<detailed_description>This Phase 1b multicenter , randomize , double-blind , placebo-controlled multiple dose study design evaluate safety tolerability SER-287 , evaluate microbiome alteration pharmacodynamics associate 2 dose regimen SER-287 adult subject mild-to-moderate ulcerative colitis ( UC ) .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Ulcerative colitis diagnose routine clinical , radiographic , endoscopic pathologic criterion ( preferably confirm colonoscopy pathology record within last 2 year unavailable , need approval medical monitor ) Active mildmoderate UC determine sigmoidoscopy within approximately 3 day randomization study 1 . Fever &gt; 38.3Â°C 2 . Known suspected toxic megacolon and/or know small bowel ileus 3 . Known history Crohn 's disease 4 . Subjects serum albumin &lt; 2.5 g/dL baseline 5 . CMV polymerase chain reaction ( PCR ) positive blood plasma screen 6 . Known stool study positive ova and/or parasites stool culture within 30 day enrollment 7 . Subjects cyclosporine triple immunosuppression , Triple immunosuppression include three follow class drug take combination : steroid ( i.e. , prednisone/budesonide/budesonide MMX ) , immunosuppressant ( i.e. , methotrexate/azathioprine/6mercaptopurine ) , and/or immunosuppressant ( i.e. , tacrolimus , cellcept ) . 8 . Biologic medication ( infliximab/ adalimumab/ golimumab/ certolizumab/vedolizumab/ustekinumab/natalizumab ) use within 3 month prior screen 9 . Known active malignancy except basal cell skin cancer , squamous cell skin cancer 10 . Subjects previous colectomy , ostomy , Jpouch , previous intestinal surgery ( exclude cholecystectomy , appendectomy ) 11 . Subjects know history celiac disease gluten enteropathy 12 . Subjects Clostridium difficile positive stool Screening Visit 13 . Antibiotic use within prior 1 month randomization 14 . Expected receive antibiotic within 8 week sign Informed Consent Form ( ICF ) ( i.e. , planned/anticipated procedure ) 15 . Received investigational drug within 1 month study entry 16 . Received investigational antibody vaccine within 3 month study entry 17 . Previously enrol SER109/SER287 study 18 . Received FMT within last 6 month 19 . Subjects anatomic medical contraindication flexible sigmoidoscopy , include necessarily limit toxic megacolon , gastrointestinal ( GI ) fistula , immediate postoperative status abdominal surgery , severe coagulopathy , large symptomatic abdominal aortic aneurysm , subject study physician deems subject significant risk complication flexible sigmoidoscopy 20 . Unable stop steroid enema suppository mesalamine enemas suppository screen visit 21 . Unable stop opiate treatment unless stable dose increase dose plan duration study 22 . Unable stop probiotic screen visit 23 . Concurrent intensive induction chemotherapy , radiotherapy , biologic treatment active malignancy ( subject maintenance chemotherapy may enrol consultation medical monitor ) 24 . Known allergy intolerance oral vancomycin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>